Mesoblast is using its proprietary mesenchymal lineage cell technology platform to develop and commercialize innovative allogeneic cellular medicines to treat complex diseases where inflammation plays a central role and are resistant to conventional standard of care.
The Company’s broad portfolio of late-stage product candidates are:
- RYONCIL™ (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD) in children
- REVASCOR® for advanced chronic heart failure
- MPC-06-ID for chronic low back pain due to degenerative disc disease
In January 2020, Mesoblast filed a Biologics License Application with the United States Food and Drug Administration to seek approval of RYONCIL in pediatric acute GVHD. Mesoblast is developing remestemcel-L for rare diseases in adults and children and has a promising emerging pipeline of Phase 2 product candidates and next generation technologies.
Innovative technology platform
Mesoblast’s novel allogeneic product candidates are based on rare (approximately 1:100,000 in bone marrow) mesenchymal lineage cells that respond to tissue damage, secreting mediators that promote tissue repair and modulate immune responses.
Mesenchymal lineage cells are collected from the bone marrow of healthy adult donors and proprietary processes are utilized to expand them to a uniform, well characterized, and highly reproducible cell population. This enables manufacturing at industrial scale for commercial purposes. Another key feature of Mesoblast’s cells is they can be administered to patients without the need for donor–recipient matching or recipient immune suppression.
